Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 29 min 18 sec ago

Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy

Thu, 01/28/2016 - 15:25
An application is currently under review for single agent venetoclax treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including patients with the 17p deletion genetic mutation NORTH CHICAGO, Ill., Jan. 28, 2016 -- (Healthcare...
Biopharmaceuticals, Oncology, FDA
AbbVie, venetoclax, Acute Myeloid Leukemia

MetaCure Announces Appointment of New CEO

Wed, 01/27/2016 - 15:16
HAMILTON, Bermuda, January 27, 2016 -- (Healthcare Sales & Marketing Network) -- MetaCure has announced the appointment of Adrian Gilmore as CEO. Gilmore brings over 20 years' experience in the healthcare and medical device industry, and will also join t...
Devices, Endocrinology, Personnel
MetaCure, DIAMOND therapy, diabetes

BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directors

Wed, 01/27/2016 - 15:12
Veteran of corporate and civic boards adds more than 20 years of corporate experience to BioPharmX Board MENLO PARK, Calif., Jan. 27, 2016 -- (Healthcare Sales & Marketing Network) -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical c...
Biopharmaceuticals, Dermatology, Personnel

InnFocus MicroShunt(R) 3-Year Results of a Long Term Clinical Trial Show Long Lasting IOP Reduction

Wed, 01/27/2016 - 13:52
Patient IOP Reduced average of 55% to 10.7mm Hg MIAMI, Jan. 27, 2016 -- (Healthcare Sales & Marketing Network) -- Glaucoma patients treated in a prospective clinical trial with the InnFocus MicroShunt® Drainage System and followed for over three ye...
Devices, Ophthalmology
InnFocus, MicroShunt, Glaucoma, Intraocular Pressure

Aytu BioScience Announces Additions to Board of Directors

Wed, 01/27/2016 - 13:45
ENGLEWOOD, Co., Jan. 27, 2016 -- (Healthcare Sales & Marketing Network) -- Aytu BioScience, Inc. (AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, today announced that Josh Disbrow, Aytu's ...
Biopharmaceuticals, Urology, Personnel
Aytu BioScience, ProstaScint, capromab, Primsol

Sotera(R) Wireless Surpasses 1 Million Hours Of Continuous Vital Signs Monitoring

Wed, 01/27/2016 - 13:39
Sotera Wireless Leads Industry in Alarm Management and Performance Analytics SAN DIEGO, Jan. 27, 2016 -- (Healthcare Sales & Marketing Network) -- Sotera Wireless today announced it has surpassed the 1 million hour mark in its collection of high-fideli...
Devices, Monitoring
Sotera Wireless, ViSi Mobile System, Vital Signs Monitor

Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Wed, 01/27/2016 - 13:34
Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib is superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib[1] More patients on afatinib were free of cancer growth 18 ...
Biopharmaceuticals, Oncology
Boehringer Ingelheim, LUX-Lung 7, Gilotrif, EGFR, lung cancer

Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies

Wed, 01/27/2016 - 13:18
MENLO PARK, Calif., Jan. 27, 2016 -- (Healthcare Sales & Marketing Network) -- Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that it closed a $51 mill...
Biopharmaceuticals, Venture Capital, Mergers & Acquisitions
Adicet Bio, Applied Immune Technologies, immunotherapy

Surgical Specialties to Acquire Leading German Needle and Suture Manufacturer

Tue, 01/26/2016 - 23:24
Creates one of the largest global manufacturers of needles used in medical devices Parallel Surgical Specialties debt refinancing completed with improved terms and provides acquisition funding BRAINTREE, Mass. and JESTETTEN, Germany, Jan. 26, 2016 --...
Devices, Surgery, Mergers & Acquisitions
Surgical Specialties, FSSB Chirurgische Nadein

Varian Medical Systems Appoints Dr. Patrick Kupelian VP of Clinical Affairs

Tue, 01/26/2016 - 18:42
PALO ALTO, Calif., Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (VAR), a world leader in cancer treatment and x-ray imaging technology, today announced it has appointed Patrick Kupelian, MD to vice president of Clinica...
Devices, Oncology, Personnel
Varian Medical Systems, radiotherapy, radiosurgery, proton therapy

Abcodia Announces Expanded U.S. Availability of the ROCA(R) Test for Early Ovarian Cancer Detection

Tue, 01/26/2016 - 18:40
ROCA Test now available in 15 states and the District of Columbia BOSTON and CAMBRIDGE, England, January 26, 2016 -- (Healthcare Sales & Marketing Network) --Abcodia, a commercial stage company focused on the development of proprietary tests for the ea...
Diagnostics, Oncology, Product Launch
Abcodia, ROCA Test, ovarian cancer

Novo Nordisk Launches Tresiba(R) (insulin degludec injection 200 Units/mL) in the United States

Tue, 01/26/2016 - 15:27
Long-acting Tresiba® U-200 now available for adults living with diabetes PLAINSBORO, N.J., Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insu...
Biopharmaceuticals, Endocrinology, Product Launch
Novo Nordisk, Tresiba, insulin degludec, diabetes

Antares Pharma Announces CEO Transition

Tue, 01/26/2016 - 15:13
Robert Apple Appointed President and Chief Executive Officer EWING, N.J., Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Antares Pharma, Inc. (ATRS) today announced that its Board of Directors has appointed Robert Apple to the position of Pr...
Biopharmaceuticals, Personnel
Antares Pharma, OTREXUP, methotrexate, rheumatoid arthritis

Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Tue, 01/26/2016 - 13:29
SAN DIEGO, Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Otonomy, Inc. (OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the p...
Biopharmaceuticals, Oncology
Otonomy, Dexamethasone, Cisplatin-Induced Hearing Loss, ciprofloxacin

Contego Medical Announces Positive Clinical Data for Paladin(R) System, the First Post-Dilation Balloon with Integrated Embolic Protection(TM) Technology

Tue, 01/26/2016 - 13:22
Data presented at the Leipzig Interventional Course (LINC) demonstrates breakthrough treatment for Carotid Artery Disease RALEIGH, N.C., Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Contego Medical, an innovator in developing next generat...
Devices, Interventional
Contego Medical, Paladin System, angioplasty balloon, Embolic Protection

Codiak BioSciences Closes $61 Million Series B Financing

Tue, 01/26/2016 - 13:18
Funds increase support for world-leader in exosome biology to $92 million Codiak aims to harness exosome potential in multiple therapeutic and diagnostic areas CAMBRIDGE, Mass., Jan. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Codiak BioSc...
Diagnostics, Venture Capital
Codiak BioSciences, exosome

RenalGuard Solutions(TM), Inc., Announces New European Clinical Trial to Evaluate the Long-Term Impact of RenalGuard Therapy(R) in Patients at High Risk for CI-AKI

Tue, 01/26/2016 - 13:10
MILFORD, MA--(Healthcare Sales & Marketing Network) - RenalGuard Solutions™, Inc., an innovative renal protection company, today announced the STRENGTH trial, designed to evaluate the long-term clinical and economic impact of RenalGuard Therapy® in pat...
Devices, Interventional, Cardiology
RenalGuard Solutions, STRENGTH trial, RenalGuard, acute kidney injury

Inivata Completes £31.5 Million ($45M) Series A Fundraising Round

Tue, 01/26/2016 - 13:02
Funds to Drive Clinical Development of New Approaches to Improve Cancer Treatment and Outcomes through Liquid Biopsies CAMBRIDGE, England, January 26, 2016 -- (Healthcare Sales & Marketing Network) -- Inivata Limited, a clinical cancer genomics company...
Diagnostics, Personalized Medicine, Venture Capital
Inivata Limited, ctDNA analysis, ctDNA

Opsens hires George Quinoy as Vice President / General Manager U.S. Commercial Sales and Operations

Mon, 01/25/2016 - 18:15
QUEBEC CITY , Jan. 25, 2016 -(Healthcare Sales & Marketing Network)- Opsens Inc. ("Opsens" or the "Company") (OPS.V) (OPSSF) is pleased to announce the hiring of George Quinoy as Vice President / General Manager U.S. Commercial Sales & ...
Devices, Interventional, Cardiology, Personnel
Opsens, Fractional Flow Reserve, OptoWire, OptoMonitor

CARsgen Therapeutics Completes $30 Million Series B Financing

Mon, 01/25/2016 - 18:09
Funding to Advance Clinical Development of CAR-T Therapies for Brain, Liver and Lung Cancers SHANGHAI, Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a private and venture backed company focused on the development of C...
Biopharmaceuticals, Oncology, Venture Capital
CARsgen Therapeutics, CAR-T cell, immunotherapy

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong